Dr Javed Butler: Vericiguat in Heart Failure

Dr. Javed Butler challenges the notion of using vericiguat as a last-resort therapy for heart failure patients. In this engaging discussion, he highlights its unique mechanism of action, which complements foundational quadruple therapy for heart failure with reduced ejection fraction. Dr. Butler stresses the importance of early, proactive use of vericiguat to address worsening heart failure, improve outcomes, and reduce hospitalizations and mortality. He explains why waiting until patients are critically ill to introduce this therapy may undermine its benefits, advocating for its integration into treatment plans before patients reach advanced stages.